Acute preterm labor: diagnosis, tocolytic selection, and adjunct therapy
Preterm labor — regular uterine contractions accompanied by cervical change before 37 weeks — is a clinical diagnosis that is notoriously imprecise when based on contractions alone. Because tocolysis, corticosteroids, and antibiotic/GBS interventions carry real costs and side effects, objective adjuncts (cervical length, fetal fibronectin) are used to avoid overtreating the many patients whose symptoms do not represent true preterm labor.
Preterm labor is defined as regular uterine contractions (typically ≥4 in 20 minutes or ≥8 in 60 minutes) occurring between 20 and 37 weeks gestation, accompanied by cervical change — dilation, effacement, or both — on serial digital exam.
The core diagnostic problem is that painful, regular contractions are common and frequently resolve spontaneously without cervical change: as many as 30–50% of women admitted for "preterm labor" based on symptoms alone will not actually deliver preterm. Treating every symptomatic patient with the full bundle of interventions (tocolysis, corticosteroids, magnesium, transfer to a higher level of care) would substantially overtreat this population.
This has driven adoption of objective adjunctive tests — transvaginal cervical length measurement and fetal fibronectin — to risk-stratify symptomatic patients and reserve aggressive intervention for those genuinely likely to deliver soon.
Transvaginal ultrasound cervical length is the most reliable objective predictor of preterm delivery risk. A cervical length ≥30mm in a symptomatic patient carries a very low short-term delivery risk and generally does not require full tocolytic/corticosteroid treatment; a cervical length <20mm substantially raises risk and supports treatment; a length in the equivocal 20–29mm range often prompts fetal fibronectin testing to refine the decision further.
Cervical length shortening reflects the same underlying process (increasing prostaglandin activity, mechanical and inflammatory remodeling of the cervix) that eventually produces clinical labor, making it a direct anatomic readout of preterm labor risk rather than an indirect symptom-based inference.
Fetal fibronectin is an extracellular matrix glycoprotein that normally "glues" the fetal membranes to the uterine decidua; its presence in cervicovaginal secretions between 22 and 34 weeks (outside the normal window when it is physiologically present, before 22 weeks and after membrane-decidua separation begins near term) suggests disruption of the choriodecidual interface — a step in the pathway toward labor.
fFN's clinical value lies overwhelmingly in its negative predictive value: a negative fFN test (in the setting of a cervical length between 20–30mm) confers a >95% probability of NOT delivering within the next 7–14 days, allowing safe discharge without full treatment. A positive fFN result is far less specific and does not, by itself, mandate treatment — it is used in combination with cervical length and clinical judgment.
The single most useful piece of information from cervical length and fFN testing is a negative result — both tests are far better at ruling out imminent preterm birth than at ruling it in, which is why they are used primarily to avoid unnecessary treatment rather than to confirm the diagnosis.
No tocolytic agent prevents preterm birth outright — all available agents share the same modest goal: delaying delivery for up to 48 hours to allow antenatal corticosteroids (and, when indicated, magnesium sulfate for fetal neuroprotection and group B streptococcus antibiotic prophylaxis) to be administered before birth. Agent choice is driven primarily by gestational age and maternal contraindications rather than by superior efficacy of any one drug.
Nifedipine inhibits voltage-gated calcium channels in myometrial smooth muscle, reducing intracellular calcium influx required for actin-myosin cross-bridge cycling and uterine contraction. It has become the most widely favored first-line agent in the US given its oral route, favorable side-effect profile relative to terbutaline, and applicability across a broad gestational age range without the ductal constriction concern that limits indomethacin near term.
Maternal side effects are generally mild and dose-related: hypotension, reflex tachycardia, flushing, and headache. Because nifedipine is a vasodilator, caution (though not absolute contraindication) is advised when used concurrently with magnesium sulfate, as both agents can produce additive hypotension and neuromuscular blockade.
Indomethacin, a nonselective cyclooxygenase (COX-1/COX-2) inhibitor, reduces myometrial prostaglandin synthesis — prostaglandins (particularly PGF2α and PGE2) directly stimulate uterine contraction, so blocking their synthesis is an effective tocolytic mechanism, especially useful at earlier gestational ages.
Its defining limitation is fetal: prostaglandins (specifically PGE2) maintain patency of the fetal ductus arteriosus in utero, so COX inhibition risks premature in-utero ductal constriction, which can cause fetal pulmonary hypertension. This risk rises sharply with advancing gestational age as the ductus becomes more prostaglandin-sensitive, so indomethacin is generally avoided at or beyond 32 weeks and used with duration limits (typically <48–72 hours) and, when used near this threshold, with fetal echocardiographic monitoring of ductal flow.
Additional fetal risk: oligohydramnios from reduced fetal renal blood flow/urine output, which is usually reversible after discontinuation.
The single most important prescribing rule in this simulator: never use indomethacin at or beyond 32 weeks gestation. The ductus arteriosus becomes progressively more sensitive to COX inhibition as pregnancy advances, and constriction can precipitate fetal right heart strain and pulmonary hypertension.
Terbutaline, a β2-adrenergic receptor agonist, relaxes myometrial smooth muscle via cAMP-mediated pathways but carries a meaningfully worse maternal side-effect profile than nifedipine or indomethacin: tachycardia, palpitations, hyperglycemia, hypokalemia, and — rarely but seriously — pulmonary edema and myocardial ischemia. The FDA carries a boxed warning against use beyond 48–72 hours or for outpatient/oral maintenance use given case reports of maternal death; it is now used sparingly, generally reserved for acute short-term use or as a second-line agent.
Magnesium sulfate, historically used as a first-line tocolytic, is now recognized as a relatively weak uterine relaxant with an efficacy inferior to nifedipine and indomethacin in most comparative studies. Its major contemporary obstetric role has shifted from tocolysis to fetal neuroprotection (reducing risk and severity of cerebral palsy) when delivery before 32 weeks is anticipated, and to eclampsia seizure prophylaxis in preeclampsia — not as a primary tocolytic agent.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Nifedipine | Calcium channel blocker | Blocks myometrial voltage-gated Ca²⁺ channels | Oral, favorable safety profile, broad GA range |
| Indomethacin | COX-1/COX-2 inhibitor | Reduces prostaglandin-driven contraction | Effective <32wk; avoid ≥32wk (ductal risk) |
| Terbutaline | β2-adrenergic agonist | cAMP-mediated myometrial relaxation | Acute use only — boxed warning vs maintenance |
| Magnesium sulfate | NMDA/Ca²⁺ antagonism | Weak tocolytic; primary role is fetal neuroprotection <32wk | Reduces cerebral palsy risk/severity, not first-line tocolytic |
Every tocolytic agent carries a distinct maternal and fetal side-effect profile that must be actively monitored during administration. Effective monitoring balances two goals: confirming a therapeutic response (falling contraction frequency) while detecting early signs of agent-specific toxicity before they become dangerous.
Magnesium is renally cleared and has a narrow therapeutic-to-toxic window, so patients receiving it require hourly clinical assessment: deep tendon reflexes (loss of patellar reflex is typically the first sign of rising magnesium levels, occurring around 9–12 mg/dL), respiratory rate (respiratory depression develops around 12–16 mg/dL), and urine output (oliguria promotes magnesium accumulation, requiring dose reduction).
Calcium gluconate (1g IV over 3 minutes) is the antidote for symptomatic magnesium toxicity and should be immediately available at the bedside whenever magnesium infusion is running.
Magnesium is renally cleared exclusively, so patients with renal impairment require reduced infusion rates and more frequent level monitoring given accumulation risk.
Nifedipine requires blood pressure monitoring, particularly with the initial loading dose, given risk of maternal hypotension that can secondarily reduce uteroplacental perfusion; symptomatic hypotension prompts dose reduction or discontinuation.
Terbutaline requires continuous maternal cardiac monitoring given risk of tachycardia, arrhythmia, and — the most feared complication — pulmonary edema, which is more likely with prolonged infusion, concurrent corticosteroid administration (which itself causes fluid retention), multiple gestation, and coexisting maternal cardiac disease or occult infection (chorioamnionitis). Strict intake/output monitoring and avoidance of aggressive IV fluid administration are important preventive measures.
Fetal heart rate monitoring is maintained throughout tocolysis for all agents, both to assess fetal well-being and because fetal tachycardia can be a secondary effect of maternal terbutaline (transplacental β-agonist effect) or an early sign of intra-amniotic infection, which is itself a contraindication to continued tocolysis.
When indomethacin is used, particularly for courses extending beyond 48 hours or when used closer to the 32-week cutoff, fetal echocardiography can be used to assess ductus arteriosus flow velocity for early signs of constriction, and serial ultrasound assesses amniotic fluid volume for oligohydramnios from reduced fetal urine output.
Both effects are generally reversible within 24–48 hours of discontinuation, which is why indomethacin courses are kept short and gestational-age-limited rather than avoided altogether at earlier gestational ages where its efficacy and favorable maternal profile are advantageous.
Any sign of fetal compromise — ductal constriction, significant oligohydramnios, or non-reassuring fetal heart tracing — prompts immediate tocolytic discontinuation regardless of contraction status.
Across all agents, the presence of contraindications (chorioamnionitis, non-reassuring fetal status, severe preeclampsia, placental abruption, or a maternal condition worsened by the specific drug) is itself always a reason to withhold or stop tocolysis — tocolysis is never appropriate when continuing the pregnancy poses greater risk than delivery.
Tocolysis is designed as a short bridge, not a sustained treatment. The evidence supporting tocolytic use is specifically for delaying delivery long enough to complete a course of antenatal corticosteroids and, when indicated, magnesium sulfate neuroprotection and group B streptococcus prophylaxis — not for extending pregnancy over days to weeks. Current guidelines explicitly recommend against prolonged maintenance tocolysis.
Antenatal corticosteroids (betamethasone 12mg IM x2 doses 24 hours apart, or dexamethasone 6mg IM x4 doses 12 hours apart) accelerate fetal lung surfactant production and structural lung maturation, substantially reducing neonatal respiratory distress syndrome, intraventricular hemorrhage, and neonatal death when delivery occurs within 7 days of administration — with maximal benefit when the full course is completed and at least 24 hours have elapsed since the first dose.
Tocolysis exists specifically to purchase this 24–48 hour window: delaying delivery by even 48 hours allows the corticosteroid course to be completed and to begin exerting its maximal biological effect, converting a preterm delivery from one without steroid benefit to one with substantially improved neonatal outcomes.
This is why the 48-hour mark is the explicit target for essentially all tocolytic protocols — it is not an arbitrary number but is derived directly from corticosteroid pharmacodynamics.
Multiple randomized trials and meta-analyses have evaluated continuing tocolytic therapy beyond the acute 48-hour period (oral maintenance nifedipine, maintenance terbutaline, etc.) and consistently failed to demonstrate improvement in latency to delivery, gestational age at delivery, or neonatal outcomes compared with stopping therapy after the acute course — while continued exposure prolongs maternal side-effect risk without proportional benefit.
As a result, ACOG and other professional societies explicitly recommend against maintenance tocolysis after the acute 48-hour treatment window and against repeated courses of acute tocolysis for recurrent preterm labor episodes, favoring instead expectant management with close surveillance once the acute episode has been treated.
This represents a shift from older obstetric practice, when prolonged and repeated tocolysis courses were common, toward an evidence-based, time-limited approach.
Tocolysis works by buying time for corticosteroids and neuroprotection — not by preventing preterm birth. Once that 48-hour window has been used, continuing the tocolytic does not improve the baby's outcome and only adds maternal risk.
Magnesium sulfate for fetal neuroprotection is administered when delivery before 32 weeks is anticipated within 24 hours, using a loading dose (typically 4–6g IV) followed by a maintenance infusion (1–2g/hr); large trials (BEAM, PREMAG, MAGnet meta-analysis) demonstrate a reduction in the risk and severity of cerebral palsy in surviving infants, though overall neonatal mortality is not significantly changed.
Intrapartum group B streptococcus (GBS) antibiotic prophylaxis (penicillin G, or ampicillin; alternative agents for penicillin allergy) is administered when GBS status is positive or unknown at the time preterm delivery appears imminent, since ideally at least 4 hours of antibiotic exposure before delivery is needed to reduce neonatal early-onset GBS sepsis risk.
All three interventions — corticosteroids, magnesium neuroprotection, and GBS prophylaxis — are coordinated within the same acute admission window that tocolysis is designed to preserve, making the 48-hour period a coordinated bundle of care rather than a series of independent decisions.